| DB ID | MyCo_2575 |
| Title | Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway |
| Year | 2013 |
| PMID | 23644098 |
| Fungal Diseases involved | Invasive aspergillosis |
| Disease | Aspergillosis (Aspergillus Infection) |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This work was registered as an audit within the Cardiff and Vale University Health Board and as such Ethical approval was not required. |
| Site of Infection | Unspecified |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Mn |
| Biomarker Full Name | Mannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Between Oct 2005 and June 2009 all adult patients entered into the pathway were audited. A cohort of 549 high risk haematology and stem-cell transplant recipients was fol- lowed over a 5 year period. The routine standard of care involved the use of antimould prophy- laxis and a neutropenic care pathway utilizing twice weekly antigen and PCR testing. |
| Cohort No. | 549 |
| Age Group | > 18 |
| P Value | None |
| Sensitivity | 0.986 |
| Specificity | 0.996 |
| Positive Predictive Value | 0.218 |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Sub Technique | ELISA |
| Technique | Immunoassay |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
